NYSE - Delayed Quote • USD
Prestige Consumer Healthcare Inc. (PBH)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | 1.14 | 1.11 | 4.33 | 4.63 |
| Low Estimate | 1.14 | 1.1 | 4.33 | 4.52 |
| High Estimate | 1.14 | 1.14 | 4.34 | 4.69 |
| Year Ago EPS | -4.83 | 1.06 | -1.65 | 4.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | 287.47M | 285.36M | 1.14B | 1.16B |
| Low Estimate | 286.65M | 283.19M | 1.14B | 1.16B |
| High Estimate | 289M | 286.29M | 1.14B | 1.17B |
| Year Ago Sales | 285.87M | -- | 1.13B | 1.14B |
| Sales Growth (year/est) | 0.60% | -- | 0.70% | 2.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.04 | 1.01 | 1.07 | 1.04 |
| EPS Actual | -4.83 | 1.06 | 1.07 | 1.06 |
| Difference | -5.87 | 0.05 | 0 | 0.02 |
| Surprise % | -564.40% | 5.00% | 0.00% | 1.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.14 | 1.11 | 4.33 | 4.63 |
| 7 Days Ago | 1.14 | 1.11 | 4.33 | 4.63 |
| 30 Days Ago | 1.14 | 1.11 | 4.33 | 4.63 |
| 60 Days Ago | 1.14 | 1.11 | 4.33 | 4.63 |
| 90 Days Ago | 1.14 | 1.11 | 4.32 | 4.6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PBH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 123.60% | -- | -- | 0.80% |
| Next Qtr. | 4.70% | -- | -- | 9.60% |
| Current Year | 362.40% | -- | -- | 4.50% |
| Next Year | 6.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 8.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 10.66% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | DA Davidson: Neutral to Neutral | 6/26/2023 |
| Reiterates | DA Davidson: Neutral | 5/8/2023 |
| Maintains | RBC Capital: Sector Perform | 3/17/2023 |
| Maintains | Oppenheimer: Outperform | 2/17/2023 |
| Maintains | Oppenheimer: Outperform | 1/13/2023 |
| Initiated | Canaccord Genuity: Buy | 11/17/2022 |
Related Tickers
PAHC Phibro Animal Health Corporation
13.04
+1.32%
LFCR Lifecore Biomedical, Inc.
6.32
-3.29%
RDY Dr. Reddy's Laboratories Limited
70.91
-0.56%
TARO Taro Pharmaceutical Industries Ltd.
42.19
-0.12%
CNTMF Cansortium Inc.
0.1900
-5.00%
FFNTF 4Front Ventures Corp.
0.0990
-5.71%
HCM HUTCHMED (China) Limited
16.36
-0.55%
ORGO Organogenesis Holdings Inc.
2.8600
+2.51%
INDV Indivior PLC
18.76
-2.60%
AMPH Amphastar Pharmaceuticals, Inc.
38.65
-3.50%